Advertisement
Advertisement
U.S. Markets open in 9 hrs 7 mins
Advertisement
Advertisement
Advertisement
Advertisement

DURECT Corporation (DRRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.6599-0.0199 (-2.93%)
At close: 04:00PM EST
0.6700 +0.01 (+1.53%)
After hours: 05:53PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6798
Open0.6682
Bid0.6700 x 1100
Ask0.6880 x 900
Day's Range0.6500 - 0.7143
52 Week Range0.6500 - 2.9500
Volume924,579
Avg. Volume745,251
Market Cap150.131M
Beta (5Y Monthly)1.15
PE Ratio (TTM)N/A
EPS (TTM)-0.1140
Earnings DateMar 02, 2022 - Mar 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
  • Zacks

    Here's Why Durect (DRRX) is Poised for a Turnaround After Losing 17.1% in 4 Weeks

    Durect (DRRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

  • PR Newswire

    DURECT Corporation to Participate in H.C. Wainwright Bioconnect Conference

    DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, and Dr. Norman Sussman, Chief Medical Officer will present at the H.C. Wainwright Bioconnect Conference which will be available on demand starting on January 10, 2022.

  • PR Newswire

    DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)

    DURECT Corporation (Nasdaq: DRRX) today announced a licensing agreement granting Innocoll Biotherapeutics plc, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, exclusive development and commercialization rights to POSIMIR® (bupivacaine solution) for infiltration use, DURECT's FDA-approved non-opioid, sustained-release local analgesic for the treatment of post-surgical pain in adults following arthroscopic subacromial decompression surgery, in the United States.

Advertisement
Advertisement